Teva and Cephalon Receive European Commission Approval For Acquisition
13 Octobre 2011 - 9:14PM
Business Wire
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Cephalon
Inc. (NASDAQ: CEPH) announced today that they received approval
from the European Commission to proceed with Teva’s acquisition of
Cephalon.
In connection with this approval, Teva is required to divest
Cephalon's marketing authorization of generic modafinil in France
and grant to the purchaser of this marketing
authorization certain additional rights with respect to the
entire European Economic Area, including a covenant not to sue
effective as of October 2012.
With this approval, the parties have now obtained all regulatory
approvals required to close the transaction and, accordingly, have
scheduled a closing date of October 14, 2011.
About Teva
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading
global pharmaceutical company, committed to increasing access to
high-quality healthcare by developing, producing and marketing
affordable generic drugs as well as innovative and specialty
pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is the world's largest generic drug
maker, with a global product portfolio of more than 1,300 molecules
and a direct presence in about 60 countries. Teva's branded
businesses focus on neurological, respiratory and women's health
therapeutic areas as well as biologics. Teva currently employs
approximately 42,000 people around the world and reached $16.1
billion in net sales in 2010.
Teva’s Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express
the current beliefs and expectations of management. Such statements
are based on management's current beliefs and expectations and
involve a number of known and unknown risks and uncertainties that
could cause our future results, performance or achievements to
differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to successfully develop and
commercialize additional pharmaceutical products, the introduction
of competing generic equivalents, the extent to which we may obtain
U.S. market exclusivity for certain of our new generic products and
regulatory changes that may prevent us from utilizing exclusivity
periods, potential liability for sales of generic products prior to
a final resolution of outstanding patent litigation, including that
relating to the generic version of Protonix®, the extent to which
any manufacturing or quality control problems damage our reputation
for high quality production, the effects of competition on sales of
our innovative products, especially Copaxone® (including potential
generic and oral competition for Copaxone®), the impact of
continuing consolidation of our distributors and customers, our
ability to identify, consummate and successfully integrate
acquisitions (including the acquisition of Cephalon), interruptions
in our supply chain or problems with our information technology
systems that adversely affect our complex manufacturing processes,
intense competition in our specialty pharmaceutical businesses, any
failures to comply with the complex Medicare and Medicaid reporting
and payment obligations, our exposure to currency fluctuations and
restrictions as well as credit risks, the effects of reforms in
healthcare regulation, adverse effects of political or economical
instability, major hostilities or acts of terrorism on our
significant worldwide operations, increased government scrutiny in
both the U.S. and Europe of our agreements with brand companies,
dependence on the effectiveness of our patents and other
protections for innovative products, our ability to achieve
expected results through our innovative R&D efforts, the
difficulty of predicting U.S. Food and Drug Administration,
European Medicines Agency and other regulatory authority approvals,
uncertainties surrounding the legislative and regulatory pathway
for the registration and approval of biotechnology-based products,
potentially significant impairments of intangible assets and
goodwill, potential increases in tax liabilities resulting from
challenges to our intercompany arrangements, our potential exposure
to product liability claims to the extent not covered by insurance,
the termination or expiration of governmental programs or tax
benefits, current economic conditions, any failure to retain key
personnel or to attract additional executive and managerial talent,
environmental risks and other factors that are discussed in our
Annual Report on Form 20-F and other filings with the U.S.
Securities and Exchange Commission.
Cephalon (NASDAQ:CEPH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cephalon (NASDAQ:CEPH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024